Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 16, 2015 - Issue 18
Submit an article Journal homepage
321
Views
12
CrossRef citations to date
0
Altmetric
Reviews

Modulation of sensitivity and resistance to multikinase inhibitors by microenvironmental platelet factors in HCC

Rosalba D’AlessandroLaboratory of Cellular Biology, National Institute for Digestive Diseases, IRCCS “Saverio de Bellis”, Via Turi 27, Castellana Grotte, BA70013, Italy
,
Caterina MessaLaboratory of Cellular Biology, National Institute for Digestive Diseases, IRCCS “Saverio de Bellis”, Via Turi 27, Castellana Grotte, BA70013, Italy
,
Maria Grazia RefoloLaboratory of Cellular Biology, National Institute for Digestive Diseases, IRCCS “Saverio de Bellis”, Via Turi 27, Castellana Grotte, BA70013, Italy
&
Brian I. CarrLaboratory of Cellular Biology, National Institute for Digestive Diseases, IRCCS “Saverio de Bellis”, Via Turi 27, Castellana Grotte, BA70013, Italy;Visiting Professor, Program for Targeted Experimental Therapeutics, Izmir Biomedicine and Genome Center, Dokuz Eylul University, Izmir, TurkeyCorrespondence[email protected]
Pages 2773-2780 | Published online: 19 Oct 2015

Bibliography

  • Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
  • Llovet JM, Ricci S, Mazzaferro V, et al. SHARP investigators study group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.

•• This article reports the first clinical trial using sorafenib.

  • Dumas J, Sibley R, Riedl B, et al. Discovery of a new class of p38 kinase inhibitors. Bioorg Med Chem Lett. 2000;10:2047–2050.
  • Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109.

•• The paper describes the molecular target of multikinase inhibitor sorafenib.

  • Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7:3129–3140.

•• In this paper researchers demonstrate the cross-talk between sorafenib and growth factor receptors,

  • Adnane L, Trail PA, Taylor I, et al. Sorafenib (BAY 43-9006, Nexavar), a dualaction inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597–612.
  • Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66:11851–11858.
  • Matsuda Y, Fukumoto M. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol. 2011;44:183–189.
  • El-Nassan HB. Recent progress in the identification of BRAF inhibitors as anti-cancer agents. Eur J Med Chem. 2014;72:170–205.
  • Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592–603. DOI:10.1038/nrc2442.
  • Huh CG, Factor VM, Sánchez A, et al. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA. 2004;101(13):4477–4482.
  • Ke AW, Shi GM, Zhou J, et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology. 2009;49(2):491–503. DOI:10.1002/hep.22639.
  • Blivet-Van Eggelpoël MJ, Chettouh H, Fartoux L, et al. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol. 2012;57(1):108–115. DOI:10.1016/j.jhep.2012.02.019.
  • Wu J, Zhu AX. Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol. 2011;4:30. DOI:10.1186/1756-8722-4-30.
  • Mazumdar J1, O’Brien WT, Johnson RS, et al. O2 regulates stem cells through Wnt/β-catenin signalling. Nat Cell Biol. 2010;12(10):1007–1013. DOI:10.1038/ncb2102.
  • Sahin F, Kannangai R, Adegbola O, et al. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res. 2004;10(24):8421–8425.
  • Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135(6):1972–1983, 1983.e1–11: DOI:10.1053/j.gastro.2008.08.008.
  • Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol. 2010;80:550–560.
  • Worns MA, Galle PR. Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs. 2010;19:615–629.
  • Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245–255.
  • Carr BI, Cavallini A, Lippolis C, et al. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol. 2013;228:292–297.
  • Carr BI, D’Alessandro R, Refolo MG, et al. Effects of low concentrations of Regorafenib and Sorafenib on human HCC cell AFP, migration, invasion and growth in vitro. J Cell Physiol. 2013;228:1344–1350.

•• The authors demonstrate that low doses of regorafenib might also have potential for adjuvant therapy for hepatocellular carcinoma (HCC) patients.

  • Liu K, Liu S, Zhang W, et al. miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN. Oncol Rep. 2015;4:1003–1010. DOI:10.3892/or.2015.4030.
  • Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology. 2013;58(2):629–641. DOI:10.1002/hep.26369.
  • Chen X, Lingala S, Khoobyari S, et al. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J Hepatol. 2011;55(4):838–845. DOI:10.1016/j.jhep.2010.12.043.
  • Sieghart W, Pinter M, Dauser B, et al. Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. J Hepatol. 2012;57(3):592–599. DOI:10.1016/j.jhep.2012.04.034. Epub 2012 May 24.
  • Scartozzi M, Faloppi L, Svegliati Baroni G, et al. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer. 2014;135(5):1247–1256. DOI:10.1002/ijc.28772.
  • Pancoska P, Carr BI. Macro-and micro-environmental factors in clinical hepatocellular cancer. Semin Oncol. 2014;41(2):185–194. DOI:10.1053/j.seminoncol.2014.03.001.

• The authors show the role of environmental factors in hepatocarcinogenesis.

•• The authors provide evidences on a significant correlation between platelets number and tumor size.

  • Leslie M. Cell biology. Beyond clotting: the powers of platelets. Science. 2010;328(5978):562–564. DOI:10.1126/science.328.5978.562.
  • Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther. 2008;8(8):1247–1255. DOI:10.1586/14737140.8.8.1247.
  • Lesurtel M, Graf R, Aleil B, et al. Platelet-derived serotonin mediates liver regeneration. Science. 2006;312(5770):104–107.
  • Matsuo R, Nakano Y, Ohkohchi N. Platelet administration via the portal vein promotes liver regeneration in rats after 70% hepatectomy. Ann Surg. 2011;253(4):759–763. DOI:10.1097/SLA.0b013e318211caf8.
  • Yu Y, Zhou XD, Liu YK, et al. Platelets promote the adhesion of human hepatoma cells with a highly metastatic potential to extracellular matrix protein: involvement of platelet P-selectin and GP IIb-IIIa. J Cancer Res Clin Oncol. 2002;128(5):283–287.
  • Carr BI, Cavallini A, D’Alessandro R, et al. Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma cells. BMC Cancer. 2014;14(1):43.

•• This study demonstrates that platelet content influences HCC progression.

  • D’Alessandro R, Refolo MG, Lippolis C, et al. Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. BMC Cancer. 2014;14:351.
  • Refolo MG, D’Alessandro R, Lippolis C, et al. Modulation of Doxorubicin mediated growth inhibition of hepatocellular carcinoma cells by platelet lysates. Anticancer Agents Med Chem. 2014;14(8):1154–1160.
  • Dhillon AS, Hagan S, Rath O, et al. MAP kinase signaling pathways in cancer. Oncogene. 2007;26:3279–3290.
  • Sitia G, Aiolfi R, Di Lucia P, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA. 2012;109(32):E2165–E2172. DOI:10.1073/pnas.1209182109.
  • Sitia G, Iannacone M, Guidotti LG. Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatol. 2013;59(5):1135–1138. DOI:10.1016/j.jhep.2013.05.040.
  • Demers M, Wagner DD. Targeting platelet function to improve drug delivery. Oncoimmunol. 2012;1(1):100–102.
  • Demers M, Ho-Tin-Noé B, Schatzberg D, et al. Increased efficacy of breast cancer chemotherapy in thrombocytopenic mice. Cancer Res. 2011;71(5):1540–1549. DOI:10.1158/0008-5472.CAN-10-2038.
  • Song S, Wientjes MG, Gan Y, et al. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA. 2000;97:8658–8663.
  • Shen K, Cui D, Sun L, et al. Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression. J Cell Biochem. 2012;113:2086–2089.
  • Jalving M, Gietema JA, Lefrandt JD, et al. Metformin: taking away the candy for cancer? Eur J Cancer. 2010;46:2369–2380.
  • Atzori F, Traina TA, Ionta MT, et al. Targeting insulin-like growth factor type 1 receptor in cancer therapy. Target Oncol. 2009;4:255–266.
  • Kina S, Phonaphonh T, Liang F, et al. PDGFα receptor is a mediator for cisplatin-induced Met expression. Eur J Pharmacol. 2013;699:227–232.
  • Zhou T, Duan J, Wang Y, et al. Fluoxetine synergys with anticancer drugs to overcome multidrug resistance in breast cancer cells. Tumour Biol. 2012;33:1299–1306.
  • Peer D, Dekel Y, Melikhov D, et al. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res. 2004;64:7562–7569.
  • D’Alessandro R, Refolo MG, Lippolis C, et al. Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor. Cancer Chemother Pharmacol. 2015;75(6):1237–1245. DOI:10.1007/s00280-015-2751-6.

•• The authors demonstrate that EGF antagonizes regorafenib effects.

  • Huang P, Xu X, Wang L, et al. The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment. J Cell Mol Med. 2014;18:218–230.
  • Fuchs BC, Hoshida Y, Fujii T, et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology. 2014;59:1577–1590.
  • Alexia C, Fallot G, Lasfer M, et al. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol. 2004;68(6):1003–1015.
  • De La Monte SM, Tamaki SM, Cantarini C, et al. Aspartyl-(asparaginyl)-b-hydroxylase regulates hepatocellular carcinoma invasiveness. Journal of Hepatology. 2006;44:971–983.
  • Higuchi M, Masuyama N, Fukui Y, et al. Akt mediates Rac/Cdc42-regulated cell motility in growth factor-stimulated cells and in invasive PTEN knockout cells. CurrBiol. 2001;11:1958–1962.
  • Morimoto Y, Nouso K, Wada N, et al. Involvement of platelets in extrahepatic metastasis of hepatocellular carcinoma. Hepatol Res. 2014;44(14):E353–9.
  • Aishima S, Basaki Y, Oda Y, et al. High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma. Cancer Sci. 2006;97(11):1182–1190.
  • Thariat J, Bensadoun RJ, Etienne-Grimaldi MC, et al. Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004–02). Clin Cancer Res. 2012;18:5123–5133.
  • Gallardo A, Lerma E, Escuin D, et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer. 2012;106:1367–1373.
  • Huang F, Hurlburt W, Greer A, et al. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res. 2010;70:7221–7231.
  • Song RX, Chen Y, Zhang Z, et al. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J Steroid Biochem Mol Biol. 2010;118:219–230.
  • Yasunobu M, Toshifumi W, Masayuki K, et al. Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma. Int J Clin Exp Pathol. 2014;7(4):1299–1313.
  • Msaouel P, Galeas JN, Boiles AR, et al. Targeting the bone microenvironment in metastatic castration-resistant prostate cancer. Curr Drug Targets. 2015. Epub 2015 Apr 20.
  • Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27(4):462–472.
  • Li XY, Hu SQ, Xiao L. The cancer-associated fibroblasts and drug resistance. Eur Rev Med Pharmacol Sci. 2015;19(11):2112–2119.
  • Nasser MW, Elbaz M, Ahirwar DK, et al. Conditioning solid tumor microenvironment through inflammatory chemokines and S100 family proteins. Cancer Lett. 2015;365(1):11–22.
  • Tabe Y, Konopleva M. Role of microenvironment in resistance to therapy in AML. Curr Hematol Malig Rep. 2015;10(2):96–103.
  • Koti M, Siu A, Clément I, et al. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. Br J Cancer. 2015;112(7):1215–1222.
  • Romero IL, Mukherjee A, Kenny HA, et al. Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. Clin Cancer Res. 2015;21(4):680–686.
  • Matsuoka Y, Yoshida R, Nakayama H, et al. The tumour stromal features are associated with resistance to 5-FU-based chemoradiotherapy and a poor prognosis in patients with oral squamous cell carcinoma. APMIS. 2015;123(3):205–214.
  • Gomes LR, Vessoni AT, Menck CF. Three-dimensional microenvironment confers enhanced sensitivity to doxorubicin by reducing p53-dependent induction of autophagy. Oncogene. 2015. DOI:10.1038/onc.2014.461.
  • Schrader J, Gordon-Walker TT, Aucott RL, et al. Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology. 2011;53(4):1192–1205.
  • Sun Y, Nelson PS. Molecular pathways: involving microenvironment damage responses in cancer therapy resistance. Clin Cancer Res. 2012;18(15):4019–4025.
  • Meads MB, Lori A, et al. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 2008;14:2519–2526.
  • Chen H, Lan X, Liu M, et al. Direct TGF-β1 signaling between activated platelets and pancreatic cancer cells primes cisplatin insensitivity. Cell Biol Int. 2013;37(5):478–484.
  • Gridling M, Ficarro SB, Breitwieser FP. Song L et al. Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics. Mol Cancer Ther. 2014;13:2751–2762.
  • Gomes LR, Vessoni AT. Menck CF three-dimensional microenvironment confers enhanced sensitivity to doxorubicin by reducing p53-dependent induction of autophagy. Oncogene. 2015. DOI:10.1038/onc.2014.461. [Epub ahead of print].
  • Chen DR, Lu DY, Lin HY, et al. Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer. Biomed Res Int. 2014;2014:532161.
  • Said G, Guilbert M, Morjani H, et al. Extracellular matrix proteins modulate antimigratory and apoptotic effects of Doxorubicin. Chemother Res Pract. 2012;2012:268681.
  • Nagathihalli NS, Castellanos JA, Shi C, et al. STAT3 mediated remodeling of the tumor microenvironment results in enhanced tumor drug delivery in a mouse model of pancreatic cancer. Gastroenterology. 2015. DOI:10.1053/j.gastro.2015.07.058. [Epub ahead of print].
  • Queiroz KC, Shi K, Duitman J, et al. Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance. Int J Cancer. 2014;135:2294–2304.
  • Goh BK, Tan DM, Chan CY, et al. Are preoperative blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios useful in predicting malignancy in surgically-treated mucin-producing pancreatic cystic neoplasms? J Surg Oncol. 2015. DOI:10.1002/jso.23997. [Epub ahead of print].
  • Lai Q, Castro Santa E, Rico Juri JM, et al. Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int. 2014;27:32–41.
  • Xue TC, Jia QA, Ge NL, et al. The platelet-to-lymphocyte ratio predicts poor survival in patients with huge hepatocellular carcinoma that received transarterial chemoembolization. Tumour Biol. 2015;36:6045–6051.
  • Carr BI, Guerra V, Giannini EG, et al. Significance of platelet and AFP levels and liver function parameters for HCC size and survival. Int J Biol Markers. 2014;29:e215–23.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.